temozolomide

P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360

Glioblastoma (GBM) is a primary brain tumor, and temozolomide is the first-line alkylating agent utilized as a chemotherapeutic treatment...Here, we established stable MDR1-overexpressing GBM cells and demonstrated their functional involvement in drug efflux by decreased intracellular doxorubicin accumulation and increased cell viability...The annexin V staining showed increased apoptotic cell populations upon metformin treatment, supporting the association between mitochondrial metabolism and intracellular drug accumulation. Overall, this study suggests that mitochondrial metabolism is a bioenergetic driver of MDR1 activity, and it could be a potential therapeutic target for overcoming MDR1-mediated drug resistance in GBM.

P2, N=47, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Mar 2026 | Trial primary completion date: Nov 2026 --> Mar 2026

P1, N=56, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting

P=N/A, N=189, Recruiting, Copernicus Memorial Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2029 --> Aug 2030

P1, N=24, Recruiting, University of Nebraska | Trial completion date: Mar 2027 --> Jul 2029 | Trial primary completion date: Mar 2026 --> Jul 2027

The patient initially received 2 cycles of rituximab combined with high-dose methotrexate chemotherapy...Subsequently, the regimen was adjusted to 6 cycles of cytarabine combined with temozolomide chemotherapy followed by radiotherapy for the intracranial lesion...Up to the date of follow-up, the patient's condition was stable without recurrence. Combined with literature review, this article discusses the possible mechanisms of the coexistence of dual-subtype DLBCL (clonal evolution or biclonal origin), the potential pathways of temporal muscle metastasis and the impact of subtype differences on treatment response, which provides clinical reference for the diagnosis and individualized treatment of such rare cases.

P1, N=39, Recruiting, University of Cincinnati | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Sep 2024 --> Sep 2027

Moreover, AMI suppressed the expression of PD-L1 in cells that had been exposed to or had not been exposed to radiation, whereas radiation enhanced its expression. Because AMI exhibited promising anticancer properties including an interesting, previously unknown immunomodulatory effect, it appears that its potential therapeutic should be verified in an in vivo study.

Patient-derived glioma stem-like cells (GSCs), treated with PRMT5 inhibitor (LLY-283) or transfected with PRMT5-target-specific siRNA, were treated with TMZ and subjected to in vitro functional and mechanistic studies. Furthermore, compared to monotherapy, there was a significant reduction in the proliferation marker Ki-67, while the apoptosis marker cleaved caspase 3 and the DNA damage response marker γH2AX were upregulated. Collectively, these findings identify PRMT5 as a critical regulator of the FA pathway in glioblastoma and demonstrate that PRMT5 inhibition potentiates TMZ efficacy by disrupting FA-dependent homologous recombination repair, indicating that the combination of PRMT5 inhibition and TMZ could be a novel therapeutic strategy for glioblastoma.

P3, N=96, Recruiting, Immatics US, Inc.